Klick Health Stacks Bench in London to Support Global Business Growth and Expansion
Klick Health today shared new details about the ongoing build-out of its global ecosystem, differentiated by its singular focus on health and improved patient outcomes, authentic integration modus operandi, and longstanding commitment to providing unmatched client experience. The large independent agency announced its UK-based leadership team for Europe, the Middle East, and Africa (EMEA). The news follows the appointment of EMEA Managing Director Jennifer Lambert and debut of Klick’s Asia-Pacific (APAC) hub in Singapore.
Lambert is joined in the London hub by industry veterans Ankita Batla, January Coyle, Preeti Moseman, Tara Page, Michael Smith, and Adrian Swift, as the team celebrates 13 wins at last week’s Creative Floor Awards and its stellar showing at the Cannes Lions International Festival of Creativity.
“We are thrilled to be building the most innovative life sciences agency model EMEA has ever seen. While most global agencies tend to force-fit their services together, Klick teams are integrated from the start. Based on our clients’ needs, we provide them with bespoke end-to-end services to ensure authentic and borderless solutions,” Lambert said. “I am proud of the work our team is doing. In Preeti, Tara, Michael, Adrian, Ankita, and January, we have proven leaders from both the agency and client side, who deliver solutions that amplify our clients’ success.”
Lambert introduced Klick’s EMEA leadership team:
Preeti Moseman – Senior Creative Lead, EMEA
Moseman marks her return to the UK as Senior Creative Lead in London, following two years serving as a Creative Director on Klick’s New York team. An award-winning creative with over 16 years of industry experience, Moseman previously held positions at London agencies, EG+ (TBWA) and Wunderman, where she worked for a range of clients, including GSK, Johnson & Johnson, Pepsico, and Microsoft. Within the healthcare sector specifically, she has played senior creative roles on global launches in immunology, vaccines, and women’s health.
“I joined Klick because its drive for innovation aligns with my passion for crafting engaging experiences,” Moseman said. “With a multitude of diverse, global perspectives and reach, Klick offers the perfect stage to foster creativity, build impactful cross-functional teams, and collaborate on successful campaigns for our clients.”
Tara Page – Vice President, Head of Client Success,
EMEA
Heading up Klick’s UK-based Client Success team, Page is a veteran healthcare communications professional with over 25 years in the field, and is responsible for delivering an exceptional end-to-end client experience. Prior to joining Klick, Page was Global Director, Client Engagement at VMLY&R Health London, preceded by Managing Director, Sudler London, where she collaborated with top-tier pharmaceutical and biotech companies across brand lifecycles, covering therapeutic areas including, cardiovascular, hematology, oncology, and rare diseases.
“Being part of building a global life sciences agency from the ground-up and being surrounded by exceptionally kind and talented people is incredibly exciting. I’m loving the collaborative environment and the bright minds at Klick, as we work with our clients to enhance health outcomes and patients’ lives in EMEA and around the world,” explained Page.
Michael Smith – Science & Regulatory Director, EMEA
Bringing more than 17 years of experience leading in-house regulatory and healthcare compliance teams at pharmaceutical companies, Smith joins the agency world as Klick’s newest Science & Regulatory Director, EMEA. He previously served as Allergan's Director of Regulatory Affairs for the UK and Ireland. Smith has worked across aesthetic medicine, cosmetics, dermatology, medical devices, movement disorders, neurosciences, ophthalmology, and OTC, with extensive experience in UK, EU, and EMEA regulations to help ensure HCP and consumer-focussed campaigns are compliant. Smith excels in managing the complex requirements of healthcare compliance, ensuring creative teams are able to push boundaries and exceed expectations, while maintaining promotional compliance.
“I was drawn to the Klick’s team enthusiasm, professionalism, and regulatory rigour,” Smith said. “I’m excited for the opportunity to build our UK-based science and regulatory team, and serve our clients as part of the single, largest medical team integrated across a full-service agency.”
Adrian Swift – Vice President, Project Management, EMEA
With over 20 years of experience in delivery and project management roles, Swift joins Klick as Vice President, Project Management, EMEA. A seasoned leader who has worked on brands, including Coca-Cola, Centrica, and Unilever, he is adept in agile processes and managing projects for timely delivery. During his previous role as Managing Partner and EMEA PMO at Ogilvy, Swift worked on large accounts like IBM, Nestle, and The Nightingale Hospital, and led the agency’s consolidation of three regional markets into a global hub. One of his proudest career highlights was leading the team who helped expedite the establishment of temporary hospitals in the UK during the pandemic.
“My ultimate professional goal has always been to create a meaningful impact. Joining Klick and contributing to the development of something great in EMEA is an incredible opportunity to do so,” Swift said. “I’m thrilled to be part of a company that has a true entrepreneurial spirit and unique workplace culture, and eager to share my expertise in fostering agile mindsets to ensure our clients’ success.”
To further support Klick’s ongoing global expansion, Lambert also shared the following additions to the London-based team:
Ankita Batla, MBBS, MBA –
Senior Vice President
, Medical Strategy, Global
With over two decades of experience in patient engagement, health communications, and medical strategy, as well as a medical degree and an MBA, Dr. Batla specializes in research, strategy, and behaviour-change communication within pharmaceuticals, nutrition, health services, and public health and patient groups. As Klick’s Senior Vice President, Medical Strategy, Global, she focuses on the medical strategy needs of Klick’s growing number of international clients. She has also held senior medical roles at other UK-based agencies, including VMLY&R Health and WPP’s System Analytic. Prior to moving into healthcare communications, Dr. Batla served as a resident doctor in hospitals’ general medicine, pediatrics, public health, and neurology departments. As a leading expert in patient advocacy, she has served as a guest lecturer at top educational institutions in the UK, including the London School of Hygiene & Tropical Medicine, UCL Business School for Health UK, and University of West London. She is currently also pursuing her Masters degree in public health.
“A doctor by training and a patient advocate at heart, I love making connections between the numbers in science and the lived realities of people. At Klick, I have a work family that believes in this ethos,” Dr. Batla said. “Having worked and lived in different parts of the world has also given me a unique perspective in tackling health challenges and inequities across markets, and developing innovative creative strategies that can maximise access”
January Coyle – Senior Vice President, Global Strategy Enablement
Playing a key role on Klick Health’s holistic Strategy leadership team, Coyle joins its London hub as Senior Vice President, Global Strategy Enablement to ensure the effective coordination of strategy across Klick’s global markets and regions in EMEA, APAC, and LATAM. With over 20 years of experience in life sciences market research, KOL consulting, and advertising, Coyle most recently led a strategy team in Klick’s New York office for over three years. She previously served as Saatchi & Saatchi Wellness Senior Vice President, Director of Engagement Strategy for over six years. She has worked with a wide range of brands from pre-launch through LOE across therapeutic areas that include cardiovascular, metabolic, rare disease, and oncology, focussing on reaching key stakeholders in novel and engaging ways.
“It was the people and people-first culture that initially brought me to Klick. Now, I'm beyond excited to help scale the Klick magic in other markets and drive meaningful experiences for HCPs, patients, and their involved loved ones in partnership with our clients.”
Global momentum going strong
Today's announcement follows Klick joining the Healthcare Communications Council (HCC), one of the five European Association of Communications Agencies (EACA) councils, and it highlights the latest in a long line of global hires over the last year, as the agency continues to expand across APAC, EMEA, and LATAM. In June, Klick welcomed veteran agency leaders Mitchell Tan, Dr. Shraddha Tawate, Dr. Nevil Chimon, and Alvin Yeo to its APAC hub in Singapore.
“We are energized by our global momentum and how EMEA clients are responding to our unique agency model, end-to-end offerings, and success-driven approach,” Klick Health President Ari Schaefer said. “We’re excited by what the future holds.”
About Klick Health
Klick Health is the world’s largest independent commercialization partner for life sciences. For over 25 years, Klick has been laser-focused on developing, launching, and supporting life sciences brands to maximize their full market potential as a core commercialization partner. Recognized by leading global advertising authorities, Klick was named 2023 Independent Agency of the Year by Clio Health; its work has also been celebrated by Cannes Lions, D&AD, The One Show, Art Directors Club, Clios, New York Festivals Health, and the Webbys. Follow Klick Health on LinkedIn and for more information on joining Klick, go to careers.klick.com.
About Klick Group
The Klick Group of companies–Klick Health (including Klick Katalyst and btwelve), Klick Media Group, Klick Applied Sciences (including Klick Labs), Klick Consulting, Klick Ventures, and Sensei Labs–is an ecosystem of brilliant talent collectively working to maximize their people’s and clients’ full potential. Established in 1997, Klick has teams across North America, with offices in New York, Philadelphia, Toronto; global hubs in London, São Paulo, and Singapore; and plans to open more offices in Basel, Buenos Aires, Munich, Paris, and Tokyo. Klick has consistently been named a Best Managed Company and Great Place to Work. Over the last two years alone, the company has been recognized with almost 30 Best Workplace awards, including Best Workplaces for Women, Best Workplaces for Inclusion, Most Admired Corporate Cultures, Fast Company’s Best Workplaces for Innovators, FORTUNE’s Best Workplaces in New York, and FORTUNE’s Best Workplaces in Advertising.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230919111057/en/
Contact information
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom